Type 2 Diabetes Mellitus Therapeutics Market Anticipated to Reach $39 Billion by 2021

Pharmaceutical Processing reports that the global market for Type 2 Diabetes Mellitus (T2DM) therapeutics is estimated to reach $39 billion by 2021, a significant jump from 2014, when the market was valued at $23.4 billion.
According to the article:

[GBI Research’s] latest report states that this increase, which will occur across the eight major markets of the US, Canada, France, Germany, Italy, Spain, the UK, and Japan, represents a strong Compound Annual Growth Rate (CAGR) of 7.5%.
Fiona Chisholm, Associate Analyst for GBI Research, says the more recently approved drug classes, namely Glucagon-Like Peptide-1 (GLP-1) receptor agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors, and Sodium–Glucose Cotransporter 2 inhibitors, have already achieved considerable uptake and are expected to increase their market share over the forecast period.

Click here to read the entire article on Pharmaceutical Processing.